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Abstract
Background: Many aspects of autoimmune disease are not well understood, including the specificities of autoimmune
targets, and patterns of co-morbidity and cross-heritability across diseases. Prior work has provided evidence that somatic
mutation caused by gene conversion and deletion at segmentally duplicated loci is relevant to several diseases. Simple
tandem repeat (STR) sequence is highly mutable, both somatically and in the germ-line, and somatic STR mutations are
observed under inflammation.
Results: Protein-coding genes spanning STRs having markers of mutability, including germ-line variability, high total length,
repeat count and/or repeat similarity, are evaluated in the context of autoimmunity. For the initiation of autoimmune
disease, antigens whose autoantibodies are the first observed in a disease, termed primary autoantigens, are informative.
Three primary autoantigens, thyroid peroxidase (TPO), phogrin (PTPRN2) and filaggrin (FLG), include STRs that are among
the eleven longest STRs spanned by protein-coding genes. This association of primary autoantigens with long STR sequence
is highly significant (pv3:0|10{7). Long STRs occur within twenty genes that are associated with sixteen common
autoimmune diseases and atherosclerosis. The repeat within the TTC34 gene is an outlier in terms of length and a link with
systemic lupus erythematosus is proposed.
Conclusions: The results support the hypothesis that many autoimmune diseases are triggered by immune responses to
proteins whose DNA sequence mutates somatically in a coherent, consistent fashion. Other autoimmune diseases may be
caused by coherent somatic mutations in immune cells. The coherent somatic mutation hypothesis has the potential to be a
comprehensive explanation for the initiation of many autoimmune diseases.
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Introduction
I have previously provided evidence that somatic gene
conversion and/or deletion in sequence harboring long segmental
duplications is correlated with disease [1]. According to this
hypothesis, autoimmunity is a response to novel (somatically
mutated) antigens. Others have proposed a role for somatic
mutation in autoimmunity [2,3]. The remarkable extent of
somatic mutation, including copy number variation and somatic
mosaicism, has recently been elucidated, with several proposed
links to neurological disease [4–9]. The connection between
somatic mutation and autoimmunity requires that somatic
mutations be coherent [1], i.e., that the same type of mutation
occur in many cells, to the point that the somatically mutated
protein either disrupts normal function or is noticed by the
immune system as non-self. A coherent mutation may be recurrent
(occuring independently in many cells) [10] or clonal (occuring
once and replicating many times).
Somatic Mutation of Tandem Repeat Sequence
Coherent somatic mutation of the haptoglobin gene (HP) has
been observed in vivo in humans [11]. Carriers of the HP2 allele
have a segmentally duplicated 1.7kb sequence fragment within the
gene that includes two additional exons beyond the shorter HP1
allele. In an HP2 homozygote, Asakawa et al [11]. found a shorter
DNA sequence corresponding to an exact excision of one copy of
the tandem repeat. In each of several HP2 homozygotes
subsequently tested, a small but measurable concentration of the
shorter sequence was identified. Asakawa et al. argued that rare
but regular somatic deletion events occur in vivo. In the mouse, a
similar kind of somatic mutation has been observed in vivo at a
longer 70 kb segmental duplication [12,13]. The mutation
frequency was much higher than for HP in humans, presumably
due to both the longer duplicon and the fact that phenotypic
measurement was performed in gene-expressing tissues where
mutations would be more common, rather than in blood cells
[11,14]. Somatic mutation at additional loci, mediated by inverted
repeats [15] or tandem repeats [16], has been observed in vivo in
humans.
Long segmental duplications are not the only repetitive
sequence subject to high mutation frequencies. Simple tandem
repeats (STRs), including microsatellites and minisatellites that are
highly mutable in germ-line cells, are also mutable in somatic cells
[17,18]. Some STRs encode proteins, and somatic mutations
would generate novel, potentially immunogenic proteins. While
not strictly an STR, such an effect has been observed at the La
antigen associated with Systemic Lupus Erythematosus (SLE) and
Sjogren’s Syndrome (SJ), where somatic mutations of an 8bp poly-
A sequence into a 7 bp mutant have been observed [19]. These
mutations correlate with autoimmunity, in that about 30% of La-
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reactive SLE/SJ patients respond specifically to the mutant
protein [19] and somatic mutant DNA can be detected in such
individuals [20].
Other STRs occur within introns, where changes in repeat
counts can change splicing behavior [21]. Altered splicing of
autoantigens has been proposed as a mechanism for generating
immunogenic protein variants [22]. In particular, inflammation
can lead to reduced levels of the splicing factor ASF/SF2 [22].
Low levels of ASF/SF2 are associated with DNA double strand
breaks and DNA rearrangements triggered by R loops between
DNA and transcribed RNA [23]. R loops promote instability in
GC-rich trinucleotide repeats [24], suggesting that transcribed
repetitive sequence may be particularly vulnerable to somatic
mutation induced by ASF/SF2 depletion.
Additionally, repeat mutations are often accompanied by
significant changes in methylation [25]. Demethylation can
potentially lead to aberrant transcription initiation in the middle
of the gene sequence [26]. Repetitive sequence is also an essential
factor in cellular mechanisms for methylating nearby sequence
[27,28]. Changes to the methylation pattern can also affect
splicing [29]. Altered methylation patterns have been observed in
several autoimmune diseases [30].
Yet another reason to focus on somatic repeat mutations in
autoimmune disease is the observation that somatic tandem repeat
mutations can be induced by inflammation typical of an immune
or autoimmune response [31,32]. This observation provides the
basis for a feedback loop. An initial immune response against a
pathogen could, as a side-effect of inflammation, trigger the initial
production of aberrant protein. The aberrant protein induces a
second immune response, with further inflammation and coherent
somatic mutation in nearby cells (or remote cells opsonized by
autoantibodies [33,34]) creating a cycle of autoimmunity. Anti-
inflammatory medications reduce rates of somatic mutation in
some cancers [35], further supporting a link between inflammation
and somatic mutation,
Human STR sequence is overabundant near telomeres [18,36].
Nevertheless, the germ-line variability of a minisatellite repeat in a
population does not depend on its chromosomal location [37].
Instead, the primary determinants of minisatellite variability are (a)
the number of repeat units it contains, and (b) the degree of
identity between different repeat units within the sequence [37].
Variability is a nonlinear function of these measures: Doubling the
copy number increases the probability of being variable about 15-
fold, and adding 10% to the repeat unit similarity increases the
probability of being variable about 18-fold [37]. A more recent
model also takes into account the size of the repeat unit [38]. The
total repeat length (i.e., the product of the repeat unit size and the
repeat count) is strongly correlated with variability [38]. For
segmental duplications, high sequence identity is most important
for structural variability, with high duplicon length and low
duplicon separation also playing a role [39].
While somatic and germ-line microsatellite mutation patterns
appear similar [18], somatic and germ-line mutation patterns
differ for minisatellites [40]. Germ-line minisatellite mutations
involve recombination-based repair of double strand breaks
(DSBs), while sponteneous somatic minisatellite mutations arise
by replication slippage or mitotic recombination [40]. For somatic
mutations induced by inflammation [31,32], DNA damage
appears to be critical, including DNA strand breaks [41]. The
resulting mutation patterns in STRs may therefore more closely
resemble germ-line mutations or somatic mutations in cancer [42]
than spontaneous somatic mutations. Structural mutations in
repetitive sequence are orders of magnitude more frequent than
point mutations [43]. Mitotic mutation rates of up to 2% have
been observed in the longest human tandem repeat sequences
[44].
Autoimmunity
Autoimmune diseases have overlapping features, including
shared susceptibility loci [45–48] and cross-heritability [49].
Nevertheless, each autoimmune disease has specific manifesta-
tions, causing damage to particular organs or systems. The central
enigma of autoimmune disease is why a relatively small set of
specific proteins are immunologically targeted [50]. Many, but not
all autoantigens in systemic autoimmune diseases are proteins that
are cleaved during apoptosis [51,52], but the reason for this
association is unclear given that T cell tolerization to such cleaved
proteins is expected [52,53]. Autoantigens appear to have longer
exons and harbor more SNPs than other genes [3,54], and they
are enriched in several biologically relevant categories [3].
The most prominent phenotype of autoimmune disease is the
presence of specific antibodies (Tables 1 and 2). While T-cell
epitopes are also implicated in autoimmunity, they are more
difficult to measure [55]. Mutant protein can induce antibodies to
wild-type protein, even when T-cell tolerance to wild-type protein
is maintained [56]. Thus, antibodies are likely to provide the most
robust signal about autoimmune targets.
A B cell epitope does not have to be from the same protein
molecule as the T cell epitope in order for the B cell to be activated
by a CD4+ (helper) T cell. A B cell that endocytoses a protein
complex by binding to one of its proteins can be activated by a
CD4+ T cell specific to another protein in the complex. Such a
mechanism has been used to explain anti-TG2 antibodies in celiac
disease, where a TG2-specific B cell is activated by a CD4+ T cell
specific to gliadin after endocytosis of a TG2-gliadin complex [57].
Thus, a protein is a candidate CD4+ T cell target either if it
elicits antibodies itself, or if an in-vivo binding partner of the
protein elicits antibodies. B cell specificities (and thus antibodies) to
multiple proteins can be supported by a single CD4+ T cell
epitope. I use the term peri-antigen to mean an in-vivo binding
partner of an autoantigen. A peri-antigen can potentially function
as a CD4+ T-cell target supporting B cell specificity to the
autoantigen.
Testing the Coherent Somatic Mutation Hypothesis
I sought data to test the hypothesis that autoimmune disease is
associated with mutable repetitive sequence. Because of its
construction from long contigs [58], the reference human genome
has reliable sequence for most repetitive regions, although gaps
still remain. Because shorter reads were used, the Celera sequence
is missing the interiors of many repetitive elements [59]. Most
current sequencing technologies use short reads that must be
assembled into whole genomes. Both de-novo assembly and
alignment-based assembly are unreliable in highly repetitive
regions [60–62]. The reference human genome is therefore the
primary currently available source of robust repetitive sequence
throughout the genome.
Antibodies that develop early in disease progression provide the
strongest evidence for a causative role for the corresponding
antigen. A primary autoantigen is one whose antibodies have been
shown, in at least a subset of cases, to be the first disease-associated
antibodies to appear. A test of the coherent somatic mutation
hypothesis can be formulated as follows: Is there a statistical link
between primary autoantigens (and/or their peri-antigens) and
genes containing highly mutable sequence?
Once such a statistical link is established, a subsequent test of
the comprehensiveness of the coherent somatic mutation hypoth-
esis would consider other mutable (e.g., long STR) sequence. To
Coherent Somatic Mutation in Autoimmune Disease
PLOS ONE | www.plosone.org 2 July 2014 | Volume 9 | Issue 7 | e101093
what extent could somatic mutation at these loci explain other
autoimmune phenomena?
Results
Genes Containing Long Repeats Include Primary
Autoantigens for Common Autoimmune Diseases
Using the Tandem Repeat Finder [63] (TMRF) track of the
UCSC Genome Browser [64], I queried the database for protein-
coding genes whose DNA sequence spans STR sequence, and
filtered the results as described in the Methods. Figure 1 shows all
37 gene-internal repeats longer than 5 kb. NSUN6, TTC34, and
ANKRD36C each contain multiple long repeats, and thus appear
more than once. As previously discussed, high repeat length, high
repeat count, and high repeat identity are markers of repeat
mutability. Additionally, for intronic repeats, longer repeats are
more likely to induce long mutations that in turn are more likely to
alter methylation and splicing. At this scale, all repeats are
minisatellites with intermediate to long repeat units.
Among the eleven genes with longest repeat length are thyroid
peroxidase (TPO); protein-tyrosine phosphatase, receptor-type, n,
polypeptide 2 (PTPRN2); and filaggrin (FLG). TPO encodes a
primary autoantigen in both Hashimoto’s Thyroiditis (HT) and
Graves’ Disease (GD); PTPRN2, and FLG encode primary
autoantigens in Type-1 Diabetes (T1D) and Rheumatoid Arthritis
(RA) respectively (Table 1). The presence of three primary
autoantigens among the top eleven genes is highly significant
(pv3:0|10{7, see Methods).
Additionally, the tenth ranked gene, BRF1, encodes an RNA-
Polymerase-III (RNAP-III) initiation factor that binds to RNAP-
III [65]. RNAP-III is an autoantigen specific to Systemic Sclerosis
(SSc) (Table 1); BRF1 thus encodes a peri-antigen for SSc.
Table 1. Twenty-one of the most prevalent human autoimmune diseases, in approximately decreasing order of prevalence
[49,275].
Abbrev. Name PTPN22 Assn. B-cell Autoantigens Refs.
GD Graves’ Disease Yes [45] TPO, TG, TSHR [276]
RA Rheumatoid Arthritis Yes [143] FLG, VIM, FGA, FGB, ENO1, IgG (rheumatoid factor),
IFI16, ANXA1, PADI4
[169,178,277–282]
HT Hashimoto’s Thyroiditis Yes [143] TPO, TG [276,283]
CEL Celiac disease Unclear [284–286] TG2, HP, actin, CALR, TG3, ganglioside, collagen [57,287,288]
PSO Psoriasis No [143] PALLD, AGAP3, DSP, collagen-21, ATXN3 [289]
VIT Vitiligo Yes [290] TYR, TH, TYRP1, MCHR1, lamin A [291–293]
SJ Sjogren syndrome Unclear [294,295] SPTAN1, SPTBN1, Ro52(TRIM21), Ro60(TROVE2), La(SSB), CHRNA3,
IFI16, VIM, CHRM3
[178,296–302]
UC Ulcerative Colitis Yes [105] HMGB1, HMGB2, pANCA, tropomyosin [303–305]
AS Ankylosing Spondylitis No [306] multispecific [307]
T1D Type-1 diabetes Yes [143] PTPRN2, PTPRN, INS, GAD2, SLC30A8, VAMP2, NPY;
AMY2A (fulminant T1D)
[308–313]
AA Alopecia Areata Yes [314,315] TH, TCHH, KRT16 [316–318]
JIA Juvenile Idiopathic Arthritis Yes [319,320] DEK, HSP70, citrullinated peptides [321–324]
PA Pernicious Anemia Unknown ATP4A/ATP4B, pepsinogen A [325–327]
MS Multiple Sclerosis No [143] MAG  , MBP, PLP, MOG, CRYAB, CR1, neuronal antigens [150,151,328–332]
CD Crohn’s disease Opposite # [333] GP2, CUDZ1 [334]
SLE Systemic Lupus Erythematosus Yes [143] Ro60(TROVE2), SNRPA, APOH/cardiolipin-complex,
ribosomal P, VIM/cardiolipin-complex, La(SSB), Ro52(TRIM21),
ds-DNA, Sm, SNRNP70, SNRPC, chromatin/histones, Ku, CALR,
NCL, RF, CR1, IFI16, VIM, lamin B, F2, F2/Phosphatidylserine,
ANXA1, ANXA2, ANXA5, NPM1, HMGB1, LTF, SR proteins, others
[178,281,299,328,335–
352]
UV Uveitis No [353] CRALBP, CRYAA, CRYAB, CRYBB1 [354,355]
AD Addison’s disease Yes [356] CYP21A2 [357,358]
MG Myasthenia Gravis Yesz [359–362] AChR, MUSK, LRP4, AGRN, ColQ, TTN, KCNA1, RYR [363–365]
DM Dermatomyositis Yes [366] Mi-2-complex, IFIH1, TRIM33, MORC3, Ro52(TRIM21) [367,368]
SSc Systemic Sclerosis Yes [369,370] RNA Polymerase III, CENPB, CENPA, RNA Polymerase I,
RNA Polymerase II, TOP1, PM/Scl-complex, Ro52(TRIM21),
SNRNP70, NOR-90, Ku, Th/To, U3RNP/FBL, IFI16, ANXA5,
NPM1, HMGB1, HMGB2, Mitochondrial-M2
[211,281,299,371–375]
Autoantibodies to antigens in bold are known to be primary antibodies that occur early in disease progression, often prior to the appearance of symptoms. The
tryptophan allele of the Arg620Trp polymorphism at rs2476601 in the PTPN22 gene is associated with many autoimmune diseases, as indicated in the ‘‘PTPN22 Assn.’’
column. Atherosclerosis (CAD) is not universally considered an autoimmune disease, and is therefore not listed. Nevertheless, CAD does have autoimmune features
[376] and an association with PTPN22 [377–379]. The initial pathology in some MS lesions is associated with MAG loss [329,380,381].
#The tryptophan PTPN22 allele is protective from CD [333].
z In MG, two studies conflict about whether PTPN22 is specifically associated with the subset of cases having anti-TTN antibodies.
doi:10.1371/journal.pone.0101093.t001
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Autoimmune Associations of Genes with Long High-
Identity Tandem Duplications
Motivated by known somatic mutation of HP, I looked for
examples of long tandem duplications with at least 96% identity
occuring within protein coding genes. Since the tandem repeat
finder algorithm limits repeat units to 2000 bp, and its coverage of
some longer units appears to be incomplete (e.g., it misses the
1.7 kb repeat in HP), such repeats may have been overlooked in
the earlier analysis. The segmental duplications track of the UCSC
database [64] was used as described in the Methods.
Table 3 shows all tandem duplications of total length at least
3400 bp where at least one duplicon occurs entirely within a
protein-coding gene locus, and the tandem duplicons have the
same orientation and are separated by at most 100 bp. Several
genes appearing in Figure 1 also appear in Table 3, having long
segments that are high identity tandem repeats. Of the remaining
genes, five are autoantigens: complement component receptor 1
(CR1) in SLE and multiple sclerosis (MS); pepsinogen 4, group I
(PGA4) in pernicious anemia (PA); titin (TTN) in myasthenia gravis
(MG); interferon-gamma-inducible protein 16 (IFI16) in RA, SLE,
SSc and SJ; and HP in celiac disease (CEL) (Table 1). The
presence of five autoantigens among the top 33 genes is statistically
significant (pv0:0004, see Methods).
Copy number variations in the 54.7 kb STR of CR1 (Table 3)
have been associated with SLE [66] and Alzheimer’s disease (ALZ)
[67]. The CR1-S allele has three repeats (as in the human reference
genome) and has a population frequency of about 15%, while the
shorter CR1-F allele has two repeats and a frequency of 83% [67].
The repeat length is functionally important, since the repeat
includes sequence that codes for complement binding sites [67]. In
both SLE and ALZ, the longer CR1-S allele is the high-risk variant
[66,67]. CR1 plays an important immunological role in various cell
types [68].
PGA4 is one of three genes in the human reference genome
coding for highly similar (but not identical) versions of pepsinogen
A, an autoantigen in PA. Low levels of pepsinogen A are specific in
diagnosing PA [69]. Variant alleles observed in the population
contain three, two or one pepsinogen A gene [70]. The other
major autoantigen in PA is ATP4A/ATP4B (Table 1), which both
interacts with and colocalizes with pepsinogen A on the parietal
cell surface [71].
The HP gene that has been observed in vivo to be somatically
mutated [11] also codes for zonulin in individuals carrying the
HP2 allele [72]. The functions of haptoglobulin and zonulin are
diverse, including some specific immunological capabilities con-
ferred by the HP2 allele [72,73]. HP2 alleles are overrepresented
in several autoimmune diseases, coronary artery disease, and
mental disorders [73–77].
Additional Long Repeats Obtained from Self-Chain
Alignments
To ensure completeness of the long repeat dataset, I queried the
self-chain track of the UCSC database as described in the
Methods. These alignments capture tandem repeats that may be
slightly imperfect, i.e., there may be gaps between segments in the
alignments, as well as repeats whose unit length is above the 2 kb
threshold for TMRF. The results, shown in Table 4, are largely in
agreement with Figure 1 and Table 3. Table 4 includes the
following additional genes with alignments over 13 kb and
exhibiting germ-line structural variation (File S1): LPA, DMBT1,
MGAM, KIR3DL1, KATNAL2.
TTC34 is a Candidate CD4+ T Cell Antigen for Systemic
Lupus Erythematosus
The gene TTC34 is an outlier in Figure 1, both in terms of the
length of the repetitive segment (an underestimate because the
repeat is terminated by a gap in the human reference assembly) as
well as the number of repeat units. TTC34 encodes an
uncharacterized protein that binds to PPP4C [78]. In support of
a functional role for TTC34/PPP4C binding, RNAi depletion of
either protein induces a common elongated cell phenotype [79].
If somatic mutation of TTC34 induces autoimmunity, then
antibodies to binding partners of TTC34/PPP4C would be
expected. PPP4C is a ubiquitous serine/threonine phosphatase
that regulates a variety of cellular functions [80]. Based on the
localization of those cellular functions, I hypothesize that TTC34
mutation underlies the initial pathenogenesis of SLE. Table 5
shows that many autoantigens in SLE, including known primary
SLE autoantigens, associate with PPP4C. Under this hypothesis,
the broad array of autoantigens in SLE is a consequence of the
many functions of PPP4C, together with secondary immunoge-
nicity caused by the aberrant clearance of apoptotic cells [52,81].
The long TTC34 STR appears (with shorter length) in several
primate species, but not in more distantly related species whose
genomes have been sequenced [64]. Surprisingly, a 12 kb long
STR has independently evolved in the mouse (GRCm38) genome,
3.2 kb upstream of the mouse Ttc34 start site [82]. The mouse
Table 2. Autoantigens for selected low-prevalence autoimmune diseases.
Abbrev. Name Autoantigens Refs.
PV Pemphigus Vulgaris DSG3, DSG1, HLA-DRA, DSC3, DSC1, ATP2C1, PKP3, CHRM3, COL21A1, ANXA8L1,
CD88, CHRNE
[382,383]
RHF Rheumatic Fever VIM, MYBPC3, tropomyosin, collagen [186,384]
LEMS Lambert-Eaton Myasthenic Syndrome CACNA1A, CACNB2 [385,386]
AH1 Autoimmune Hepatitis (type 1) HMGB1, HMGB2 [387]
AH2 Autoimmune Hepatitis (type 2) CYP2D6, CES1, PDIA3 [388,389]
HA Autoimmune hemolytic anemia RHD, GYPA [390]
AP Autoimmune pancreatitis AMY2A, CA2, LTF, HSP10, plasminogen-binding protein, trypsinogens, SPINK1 [313,391]
PBC Primary Biliary Cirrhosis Mitochondrial-M2, SP100, PML, NUP210, Ro52(TRIM21), CENPB, SUMO2, SUMO1, CHRM3 [210,392,393]
NMO Neuromyelitis Optica AQP4 [329]
GPS Goodpasture’s Syndrome COL4A3 [394]
doi:10.1371/journal.pone.0101093.t002
Coherent Somatic Mutation in Autoimmune Disease
PLOS ONE | www.plosone.org 4 July 2014 | Volume 9 | Issue 7 | e101093
repeat unit length is 37, similar to the unit length of 40 in the
human repeat. As for humans, the 12 kb mouse repeat is an outlier
within the mouse genome: among all STRs that overlap a protein-
coding gene locus, including a 5 kb segment upstream of the gene,
the Ttc34 repeat is the fifth longest (Table 6). The independent
evolution of such a similar long repeat argues strongly for a
functional role.
If the TTC34 repeat mutates under inflammation [31], then the
desired functional role would be one where changes in TTC34
expression and/or PPP4C activity would be adaptive under
inflammation. PPP4C depletion makes T cells resistant to
apoptosis [83]. The association of apoptosis reduction with
inflammation is biologically plausible, since T cells in inflamma-
tory environments would be expected to receive survival signals
during normal immune responses.
LPA in Atherogenesis
LPA encodes a protein that binds to ApoB-100 in LDL particles
to form Lp(a) lipoprotein particles containing lipids, phospholipids
and cholesterol [84]. In coronary artery disease (CAD) ApoB-100
and LDL are immune targets of T cells and antibodies [85],
meaning that LPA encodes a peri-antigen for CAD. Under the
coherent somatic mutation hypothesis, rare but regular somatic
mutation to LPA would occur, analogously to that observed for HP
[11]. Epitopes of the mutant protein would be presented by
immune cells in blood vessels, leading to activation of immune
cells in atherosclerotic lesions [85] and autoimmune responses
against other components of Lp(a) lipoprotein particles. LPA is
central to CAD pathenogenesis, since an elevated plasma Lp(a)
lipoprotein level predicts stroke and vascular disease, particularly
in men [86,87]. SNPs in LPA have the largest known effect on
CAD risk [88], including an odds ratio of 1.74 for the minor allele
of rs3798220.
ABCG8 in Hypercholesterolemia
ABCG8 contains a long (10.8 kb) intronic repeat, part of a larger
compound repeat separated by a LINE insertion (Figure 2).
ABCG8 encodes a cholesterol transporter that has been implicated
in CAD [88,89] and in gallstone formation [90]. SNPs rs41360247
and rs4245791 in ABCG8 are associated with both CAD risk and
LDL cholesterol levels [89]. Additionally, the SNP rs4952688 was
shown to influence the mRNA expression of both ABCG8 and its
co-transporter ABCG5 in liver cells [91]. rs4952688 is located
within the compound repeat sequence (Figure 2), implicating this
repeat sequence (or nearby linked sequence) in the expression
levels of these two cholesterol transporters.
The normal function of ABCG8 and ABCG5 in liver cells is to
excrete cholesterol into the bile [92]. Disruption of this process
could lead to hypercholesterolemia, the initial manifestation of
atherosclerosis. ABCG8 variants can also influence cholesterol
Figure 1. Genes with long internal repeats. The x-axis denotes the total length of the tandem repeat (log-scale), and the y-axis represents the
number of repeat units within the tandem repeat (log-scale). The degree of repeat identity reported by TMRF is indicated by the color of the data
point. Genes in bold have exonic sequence overlapping the repeat. Genes containing multiple disjoint long repeats appear more than once.
doi:10.1371/journal.pone.0101093.g001
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levels by modulating cholesterol absorption [93]. Somatic repeat
mutations accumulating over time could change expression levels
of these proteins, thereby altering the rate of cholesterol excretion/
absorption. Germ-line mutations in these genes are associated with
premature atherosclerosis [91,94], as are mutations in other
cholesterol transporters such as APOE [95,96].
In principle, somatic repeat mutations could induce the
production of aberrant ABCG8 protein variants that would be
immunogenic, as previously argued for autoimmune disease.
Antibodies to such variants could interfere with cholesterol
excretion, but ABCG8-specific antibodies have not been docu-
mented in CAD. The molecular mechanisms by which the
proteins encoded by ABCG8 and ABCG5 transport cholesterol are
not fully understood [97]. If the ABCG5/ABCG8 complex binds
to LDL, then ABCG8 would encode a peri-antigen for CAD since
oxidized LDL is an autoantigen [85].
DMBT1, FCGBP, and the Mucins MUC4, MUC5B, MUC12
and MUC17
Mucins including MUC4, MUC12 and MUC17 are important
for intestinal integrity and have previously been associated with
both ulcerative colitis (UC) and Crohn’s disease (CD) [98–100].
MUC17 depletion increases epithelial permeability in the face of
E. coli exposure [101]. FCGBP is a component of the mucus layer
coating of the intestinal tract [102], and expression is higher in
several autoimmune diseases [103]. The DMBT1 protein also
provides mucosal protection of the intestine, and expression levels
correlate with disease activity in CD and UC [104]. Host-microbe
interactions appear to be central to the pathogenesis of UC and
CD [105]. CD, UC, psoriasis (PSO) and ankylosing spondylitis
(AS) have common features [105,106] that suggest a cluster of
diseases with related etiology. AS has been associated with the gut
microbiome [107], and PSO has been associated with intestinal
yeast infections [108].
A critical clue is provided by the PTPN22 rs6679677 C/A
polymorphism that is in high linkage disequilibrium with the
rs2476601 C/T polymorphism associated with many autoimmune
diseases [109]. At rs6679677, the A allele appears to be a risk allele
for UC (as for most other autoimmune diseases) but protective for
CD [105]. In the context of the coherent somatic mutation
hypothesis, one could interpret this opposite PTPN22 association
in terms of alternative responses to somatic mutation. UC would
be caused by an autoimmune response against the mutant protein,
while CD would be caused by the failure of the mutant protein’s
function, in the absence of a direct immune response against that
protein. This interpretation is consistent with a clear role for MHC
alleles in UC but not CD [105,110], and with a reduction in
mucus quantity and/or goblet cell density specifically in UC
[111,112].
CD and UC have opposite risk alleles for NOD2 polymorphisms
[105]; NOD2 variation modulates adaptive immune responses to
microbial antigens [113], and regulates DMBT1 expression in CD
[114]. Significantly, short alleles of the DMBT1 tandem repeat
that encode fewer bacterial recognition sites are overrepresented in
CD but not UC [104]. DMBT1 has high protein homology with
the CD autoantigen CUZD1 [115], potentially leading to cross-
reactive antibodies. Further, DMBT1 -coded protein binds to
pancreatic amylase [116,117] that in turn binds to the CD
autoantigen GP2 [118], meaning that DMBT1 encodes a peri-
antigen for CD.
In Sjogren’s sydrome, a primary initiating change is the
dysregulation of mucins [119], including the aberrant exocytosis
of MUC5B [120]. MUC4 is an interesting somatic mutation
candidate because its expression pattern in the eye, vagina,
ectocervix, trachea, and salivary gland [121] closely aligns with
locations where symptoms occur [122]. MUC5B is expressed in
many of these tissues [123], but not in the tear fluid [124].
Somatically mutated mucins could induce an immune response
against the mutant protein. Alternatively, aberrant mucin protein
may offer reduced protection of epithelial cells, making them
vulnerable to infection. Apoptosis of the epithelial cell could
trigger the induction of antibodies to apoptotically generated
proteins in Sjogren’s syndrome.
Table 3. Long tandem duplications with at least 96% identity
that occur within a gene locus.
Gene Length Copies Gap Coding
NBPF20 76181 2# 55 Y
NBPF8 65137 2 0 Y
CR1 54708 3 0 Y
ANKRD30A 47663 2 2 Y
RBMY1A1 47081 3 0 Y
NBPF12 44119 2# 31 Y
PGA4 37662 2 0 Y
TRPM3 35986 2 0 N
FCGBP 31945 2 0 Y
NEB 31782 3 0 N
NKG2-E z 30864 2 0 Y
TBC1D3C/TBC1D3H 27063 2 0 N
HCAR1 26136 2 14 Y
TTC34 22675 2# 22 N
DAZ1 21690 2 0 Y
NBPF1 12620 2 17 Y
NBPF12 12568 2# 4 Y
BRF1 11321 2# 0 N
C2orf78 10103 2 58 Y
CLEC17A 8924 2 0 Y
TTN 8521 2 0 Y
SNTG2 8383 2# 1 N
IFI16 8282 2 0 Y
MUC5B 7627 2# 1 Y
SPDYE3 7020 5 0 Y
ERC1 5850 2# 23 N
HRNR 5637 2# 0 Y
ACRC 4289 2 66 Y
SPRN 4144 2 0 N
TMEM132D 3907 2# 12 N
HP/HPR 3431 2 4 Y
Duplications were identified as described in the Methods. The length indicates
the total length of the high-identity tandem duplicons. The gap is the
separation between the two highest-identity (long) duplicons, which was
required to be less than 100 bp. The duplication is ‘‘coding’’ if a duplicon
overlaps at least one exon.
FCGBP has a third duplicon, but with less than 96% identity.
#These genes have duplicons that are themselves STRs of lower fidelity; only
the copy number for the high-identity long tandem duplication is reported in
this table.
zThe segmental duplication containing NKG2-E overlaps the three genes
KLRC1, KLRC2 and KLRC3.
doi:10.1371/journal.pone.0101093.t003
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Long Repeats Reside in Genes Expressed in Immune Cells
and Implicated in Autoimmunity
KIR3DL1 encodes an inhibitory receptor expressed on natural
killer (NK) cells and T cells [125]. There is a high degree of copy
number variation of the KIR genes around this locus, and some
haplotypes do not possess KIR3DL1 [126]. HLA-Bw4 is the ligand
for KIR3DL1, and is protective in MS [125] and primary
sclerosing cholangitis [127]. The presence of KIR3DL1 is
protective for AS [128], particularly AS with uveitis (UV) [129].
Somatic mutations to KIR3DL1 could reduce inhibition of NK
cells and/or T cells, leading to selective activation and clonal
expansion.
The segmental duplication at the NKG2-E locus overlaps the
genes KLRC1, KLRC2 and KLRC3. Copy number variation at
NKG2-E (manifested as a deletion of KLRC2) is associated with
psoriasis susceptibility [130]. Reduced KLRC2 expression in T cells
is observed in PSO [131], and enhanced expression of KLRC2 on
CD4+ T cells is observed in MS [132]. KLRC1 encodes a critical
receptor on NK cells, regulating the elimination of autoreactive
CD4+ T cells in animal models of MS [133]. KLRC1 plays a
critical role in tolerization by regulatory T cells [134], and is
downregulated in PSO [135].
KIR3DL1 and KLRC1 encode NK cell receptors. NK cells and
their receptors regulate autoimmunity in MS [136], and NK cell
populations rise and fall in ways that correlate with the
development of lesions in relapsing-remitting MS [137,138]. NK
cells are found in psoriatic plaques, and circulating NK cells are
reduced in PSO, MS, SLE and T1D [139,140].
The segmental duplication within the long HCAR1 repeat
identified in Tables 3 and 4 covers the two genes HCAR2 and
HCAR3. HCAR2 codes for a niacin receptor that is expressed on
antigen presenting cells and functions in a tolerization pathway for
T cells [141]. Niacin administration ameliorates an animal model
of MS through this pathway [141].
Summary: Long Simple Tandem Repeats in
Autoimmunity
Table 7 summarizes the autoimmune associations of genes with
long STRs. This key table shows that long STRs within twenty
genes are associated with sixteen common autoimmune diseases
and atherosclerosis. Each of these putatively mutable STRs
exhibits germ-line structural variation (File S1), consistent with a
somatically mutable locus. The coherent somatic mutation
hypothesis thus has the potential to be a comprehensive
explanation for many autoimmune diseases.
With the exception of MS and possibly PA and SJ, each of the
diseases associated with an autoantigen or peri-antigen in Table 7
is influenced by the functional rs2476601 single-nucleotide
polymorphism in the PTPN22 gene (Table 1). This polymorphism
specifically influences T cell signaling [142,143], B cell signaling
[144,145], autoreactive B cell generation [144], and T cell and
dendritic cell hyper-responsiveness [146]. The role of PTPN22 in
some but not all autoimmune diseases suggests a common
Table 4. Long (w5 kb) regions of self-alignment within protein-coding genes.
Gene Length Gene Length
NBPF10 45133 MTUS2 10090
ANKRD30A 40083 ANKRD36 8739
NBPF20 39623 PTPRN2 8649
DAZ2 38211 FAM153A 8495
DAZ1 36567 TTC34 8343
LPA 35017 FAM153B 7969
NBPF12 32343 FLG 7934
FCGBP 30167 BRF1 7650
DMBT1 26579 ST3GAL4 6583
MGAM 24595 TTN 6447
DAZ4 23181 MUC12 6346
KIR3DL1 22943 MUC5B 6303
NEB 20252 GALNT9 6290
ANKRD30B 18603 TRHDE 6161
NBPF8 14249 ERC1 5794
TBC1D3C 13432 ROBO2 5789
TBC1D3H 13432 TM4SF2 5498
NBPF1 13424 NBPF14 5345
KATNAL2 13368 CACNG7 5304
CR1 12971 SNTG2 5229
HCAR1 12648 TNXB 5227
POTEJ 12480 MAGEA4 5091
DAZ3 12115 ASMT 5021
Sequences with a self-similarity score of 60 or above having both query and target mapped within a protein-coding gene locus were obtained from the self-alignment
track [267] of the UCSC database as described in the Methods, and ranked by match-length. In this table, the match length corresponds to the length of identity
between the two duplicons. Note that self-aligned duplicons may overlap.
doi:10.1371/journal.pone.0101093.t004
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underlying pathway for this subset of diseases [45,143] that may be
related to STR length and/or mutability.
Table 8 shows that the conditions associated with autoantigens/
peri-antigens above have a high degree of co-morbidity and/or
familial association. Taken together, the data support the following
model for this subset of diseases:
N For each gene containing a mutable repeat locus, individuals
have a small population of somatically mutant cells.
N Under normal conditions, these mutant cells either induce
peripheral tolerance or are too rare to trigger an immune
response.
N Under inflammatory conditions (e.g., during an infection) the
population of mutant cells increases, concurrently with
immune system stimulation.
N In individuals with impaired tolerance or with sensitive B-cell or
T-cell activation thresholds, reactions against mutant cells occur.
N Inflammation caused by immune reponses induces new
coherent mutation in neighboring cells, and creates a cycle
of autoimmunity.
A disjoint subset of diseases, including MS, PSO, UV, and AS
have no association with the PTPN22 gene polymorphism
(Table 1). All four of these conditions are associated with
immune-cell expressed genes spanning long repeats. Somatic
mutation in those genes, rather than in antigenic genes, may be
the critical step for such diseases.
A Repeat Constituting 97% of the Intron Sequence within
an Autoantigen for Pemphigus Vulgaris
Somatic repeat mutations in introns could be particularly
disruptive when the intron is almost exclusively tandem repeat
Table 5. Correspondence of PPP4C localization with many known SLE autoantigens.
Autoantigen(s) Putative PPP4C function/localization
SNRPA, SNRPC, SNRNP70, Sm These are spliceosome proteins. PPP4C is involved in spliceosome assembly [80,395].
SR proteins SR proteins associate with the spliceosome [396]. See SNRPA, SNRPC, SNRNP70, Sm.
chromatin/histones PPP4C binds to HDAC3, a histone deacetylase [397]. A PPP4C complex dephosphorylates c-H2AX histones [398].
ds-DNA Stabilisation of stalled replication forks [80], histone deacetylation [397], histone dephosphorylation [398].
Ku70, Ku80 Ku70 and Ku80 associate with c-H2AX histones during double strand break repair, mediated by DNA [399,400]. A
PPP4C complex dephosphorylates c-H2AX histones [398].
PARP1 PARP1 binds with Ku [401]. See Ku.
ribosomal P dephosphorylated during apoptosis by a caspase-induced phosphatase [402].
La(SSB) La is dephosphorylated during apoptosis by a caspase-induced PP2A-like phosphatase [403].
Ro60(TROVE2) See La; Ro60 and La are components of a common protein/RNA complex [404].
APOH/cardio-lipin-complex APOH (coding for beta 2 glycoprotein I) associates with ANXA2/TLR4/CALR/NCL complexes [405]. Anti-APOH
antibodies target bound APOH, triggering NF-Kappa B activation in a TRAF6/MyD88 dependent fashion in endothelial
cells [405-407]. PPP4C physically interacts with TRAF6, and is recruited to the TLR4 complex on lipopolysaccharide
(LPS) stimulation [408]. Further, LPS stimulation induces expression of PPP4C [408].
VIM/cardiolipin-complex, VIM Vimentin is also observed in analysis of APOH/ANXA2/TLR4/CALR/NCL complexes [405]
NPM1 NPM1 binds cardiolipin [350]. See APOH/cardiolipin-complex.
CALR CALR may be dephosphorylated by an okadaic-acid-sensitive protein phosphatase [409]. See La; CALR interacts with
the Ro60/La/RNA complex [410]. See also APOH/cardiolipin-complex.
Ro52(TRIM21) See CALR; Ro52 and CALR are binding partners [410].
NCL See APOH/cardiolipin-complex.
ANXA2 See APOH/cardiolipin-complex.
F2/Phosphatidyl-serine, F2 Phosphatidylserine bound by ANXA2 [411]. See ANXA2.
ANXA1 Binds ANXA2 [412], phosphatidylserine [413], and colocalizes with ANXA5 [413]. See ANXA2, F2/Phosphatidylserine.
ANXA5 Binds phosphatidylserine as a monomer or dimer [414] and colocalizes with ANXA1 [413]. See ANXA1, F2/
Phosphatidylserine.
HMGB1 Binds phosphatidylserine [415]. See F2/Phosphatidylserine.
LTF Binds to TLR4 and activates the TRAF6/MyD88 pathway [416]. See APOH/cardiolipin-complex.
Primary autoantigens are in bold.
doi:10.1371/journal.pone.0101093.t005
Table 6. Murine long (w8 kb) STRs overlapping protein-
coding RefSeq gene loci, including 5 kb upstream of the gene
start site.







The smallest repeat unit for each region is given together with the total STR
length. The Ttc34 repeat ends 3.2 kb upstream of the gene start site.
Two adjacent repeats reported by TMRF have similar repeat structure, and
have been combined.
doi:10.1371/journal.pone.0101093.t006
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sequence. I therefore queried the reference genome for genes
containing introns where a single tandem repeat occupies a large
fraction of the intron (Table 9). The top-ranked gene in this
analysis is PKP3, containing a 2310 bp repeat occupying over 97%
of the eighth intron. There is germ-line structural variation at this
locus in the HapMap population, with deletion variants encom-
passing almost the entire STR sequence [147].
PKP3 encodes an autoantigen in pemphigus vulgaris (Table 2).
Furthermore, PKP3 binds in vivo to several other primary
pemphigus vulgaris autoantigens including DSG3, DSG1,
DSC1, and DSC3 [148]. Aberrant PKP3 could therefore serve
as a CD4+ T cell antigen in the induction of antibodies to these
other proteins. The p value for the top gene being an autoantigen
is 0:02 (see Methods).
Genes with High Copy-Number Internal Repeats Include
Autoantigens for Multiple Sclerosis and Myasthenia
Gravis
Figure 3 shows repeats of length up to 5 kb with repeat counts
of at least 700 units. At this scale, all repeats are microsatellites
with short repeat units. The genes with the eleventh and twelfth
highest repeat counts genomewide are MUSK and MAG respec-
tively. MUSK encodes an autoantigen in myasthenia gravis
(Table 1). MAG encodes a multiple scleroisis autoantigen that
binds in vivo to MBP and PLP [149], two other MS autoantigens
(Table 1). Anti-MAG antibodies have also been observed in
various polyneuropathies [150–152]. The presence of two
autoantigens among the top twelve is statistically significant
(pv0:022, see Methods). On the other hand, the STRs in MAG
and MUSK do not exhibit germ-line structural variation at 50 bp
resolution (File S1); germ-line variation would be expected for a
somatically mutable locus.
Discussion
Somatic mutation has been overlooked or discounted as a cause
of autoimmunity, primarily because ‘‘random’’ mutation would
not lead to consistent and specific disease characteristics [153].
However, many kinds of somatic mutation are nonrandom, caused
by mechanisms that yield coherent mutation patterns both within
and across individuals. Coherent somatic mutation is a unifying
and biologically plausible hypothesis to explain the specific targets
of autoimmune disease.
Longer-Range Segmental Duplications
Long high-identity segmental duplications that are not strict
tandem repeats may still lead to somatic protein changes via
deletion or duplication if they partially overlap genes. Examples of
this pattern include: RHD and GYPA, autoantigens in autoim-
mune hemolytic anemia; AMY2A, an autoantigen in autoimmune
pancreatitis and fulminant T1D, and a binding partner of the CD
autoantigen GP2 [118]; CES1 and PDIA3, autoantigens in type-2
autoimmune hepatitis; TYR, an autoantigen in vitiligo; and
CHRNA7, an autoantigen observed in schizophrenia (Tables 1
and 2, [154]). The genomic structure of TYR makes it particularly
susceptible to gene conversion and deletion (Figure 4).
The human genome contains segmental duplications that span
whole genes, and copy number variation in these tandem repeats is
likely to affect gene dosage [155]. These duplications are not
considered in the primary anaylsis since repeat-dependent somatic
mutation via deletion and/or duplication is less likely to induce
altered protein. Nevertheless, the potential for altered protein
exists through gene conversion or other processes that combine
sequence from multiple instances of the gene. The primary
autoantigen in Addison’s disease is encoded by CYP21A2 (Table 1),
which resides within a segmentally duplicated region and is a
known locus of germ-line gene conversion [156].
A five gene cluster (GH1, GH2, CSH1, CSHL1, CSH2) on
chromosome 17 resides in a region characterized by complex
segmental duplications with identity ranging from 92% to 96%.
This cluster is a hot-spot for germ-line gene conversion [157].
Variations in these genes are associated with metabolic syndrome
later in life [158]. Anti-pituitary antibodies are observed in
conjunction with type-2 diabetes [159,160] and GH1 is one of the
autoantigens [161]. GH1 codes for human growth hormone, and
growth impairment is observed in celiac disease in conjunction
with anti-pituitary antibodies [162].
Mechanisms of Coherent Somatic Mutation
PTPRN2 is an outlier not just in the length of its repetitive
sequence; it has the most predicted sites of R loop formation in the
whole genome [163]. The R loop sites do not overlap the 12 kb
repeat in PTPRN2, but several long R loop sites occur about 20 kb
upstream of this repeat. These R loops may contribute to the
instability of the repeat region, and implicate mis-splicing [22] of
PTPRN2 in T1D.
Coherent somatic mutation can occur through a variety of
mechanisms besides repeat instability and gene conversion,
discussed below and summarized in Table 10.
RAG-mediated Somatic Recombination and Rheumatoid
Factor
Cancer studies provide valuable information about coherent
somatic mutation in vivo. Many cancers elicit antibodies that are
also found in autoimmune disease [164], further supporting a role
for somatic mutation in autoimmunity. A striking example of
coherent somatic mutation in cancer is the gene IKZF1. Internal
IKZF1 deletions occur in over 80% of cases of BCR-ABL1 acute
lymphoblastic leukemia (ALL) [165]. Consistent breakpoints
suggest aberrant RAG-mediated recombination [165]. The
mutations coincide with a transition in the cancer from Chronic
Lymphocytic Leukemia (CLL) to ALL.
CD5 expression on B cells is a common feature of both RA and
CLL [166], CD5 expression correlates with RAG activity in B cells
Figure 2. Structure of the long ABCG8 repeat in the human reference genome. A 10.8 kb repeat and a 4.1 kb repeat have closely related
repeat unit sequence, and are separated by a 1.4 kb LINE insertion. The SNP rs4952688 occurs in the middle of the 4.1 kb repeat.
doi:10.1371/journal.pone.0101093.g002
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of people with autoimmune disease [167], and RAG is expressed
in B cells in the RA synovium [168]. In RA, the appearance of
rheumatoid factor (RF, an antibody to Fc-IgG) correlates with the
hypogalactosylation of IgG, occuring roughly two years after the
appearance of antibodies to citrullinated proteins, but two years
before RA diagnosis [169]. RF is detected in several other
autoimmune and infectious diseases [170].
If the RAG-dependent IKZF1 mutations that consistently occur
in ALL also occur in RA B cells, possibly followed by clonal
expansion, then aberrant glycosylation would be explained
because IKZF1 appears to be critical for proper IgG glycosylation
[171]. The improperly glycosylated IgG would be immunogenic.
In the context of a normal immune response to a pathogen, a
somatic mutation to IZKF1 could be adaptive, because it would
lead to RF production and potentially enhanced clearance of
Table 7. Known links between genes with long STRs and human autoimmune diseases.





CR1 SLE Autoantigen Yes Yes
CR1 MS Autoantigen
PGA4 PA Autoantigen Yes
TTN MG Autoantigen
IFI16 SLE, SSc, RA, SJ Autoantigen Yes
HP CEL Autoantigen Yes Yes
BRF1 SSc Peri-antigen
TTC34 SLE Peri-antigen
LPA CAD Peri-antigen Yes Yes
ABCG8 CAD Peri-antigen? Yes
DMBT1 CD Peri-antigen Yes Yes
DMBT1 UC Yes
MUC4, MUC12, MUC17 CD, UC Yes
MUC5B SJ Yes
HP RA, SLE, CD, CAD, SSc Yes
HP T1D Yes Yes
FCGBP several Yes
KLRC2 PSO Yes Yes
KLRC2 MS Yes
KIR3DL1 AS, UV Yes
Genes with long STRs come from Figure 1, Table 3 and Table 4. A bold autoantigen label corresponds to a known primary autoantigen. The CNV column indicates
whether a germ-line STR length variant is associated with the disease. Gene expression changes during disease are also shown.
While many genes qualify as encoding peri-antigens in SLE, TTC34 encodes a peri-antigen for many autoantigens (Table 5).
doi:10.1371/journal.pone.0101093.t007
Table 8. Co-morbidity and/or familial associations between six autoimmune diseases and atherosclerosis.
GD RA T1D SLE SSc CAD
HT [417] [49,418,419] [49,418] [49,419,420] [419] [421]
GD [417] [422] [417] [423] [421]




Comorbidity may reflect common susceptibility factors or secondary disease effects, such as inflammation in RA contributing to CAD risk [427]. Comorbidities with some
of these diseases exist for alopecia areata [428,429], vitiligo [430,430,431], juvenile idiopathic arthritis [432], myasthenia gravis [433,434], and Addison’s disease [435], five
additional PTPN22 -associated diseases, as well as celiac disease [436,437] and pernicious anemia [438,439].
A link between GD and CAD is potentially confounded by the anti-atherogenic properties of thyroid hormones [440].
doi:10.1371/journal.pone.0101093.t008
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immune complexes [172]. However, in the context of an
autoimmune response, RF production could increase the severity
of disease [172]. RF is also found in SLE [173], and reduced
IKZF1 expression has been associated with SLE [174,175].
Mutagens and Oxidative Stress
Cigarette smoking is mutagenic, and appears to be selectively
associated with antibodies to the primary autoantigens encoded by
ENO1 [176], VIM [177], and FGB [177] in RA. VIM mutations
induced by oxidative stress influence antigenicity [178]. The
association of RA with smoking is strong only among individuals
with particular HLA alleles. A similar phenomenon occurs in MS
[179]. This interaction of mutagen, autoantigen and HLA suggests
that mutation is pathogenic primarily when the mutant epitope is
well-presented by the corresponding antigen presenting molecules.
Clonal Expansion Following Somatic Mutation
Somatic mutations in the TSHR gene are relatively common
[180] and can induce activation and clonal expansion in thyroid
tissue [181,182], potentially explaining TSHR-antigenicity in GD.
Paraneoplastic autoimmunity [164,183,184] is a related phenom-
enon in which an immune response to a tumor expressing mutant
antigens also affects normal tissues expressing wild-type proteins.
Pathogen-Induced Protein Binding and Modification
A pathogen-expressed protein that binds with an endogenous
protein complex could serve as a CD4+ T cell target, providing
help to B cells generating antibodies to proteins in the protein
complex. A pathogen-modified endogenous protein could behave
in a similar fashion
Rheumatic Fever (RHF) is a condition characterized by
autoimmune attack against cardiac muscle, usually associated
with group A streptococcal infections [185]. There is some in-vitro
evidence of cross-reactivity of antibodies to streptococcal proteins
and autoantigens in RHF [186]. Nevertheless, there is also
evidence that mimicry may not be an important feature of RHF
[187]. Autoreactivity to collagen in RHF has been proposed to
result from collagen binding to streptococcal proteins [187].
The RHF autoantigens vimentin, myosin, and tropomyosin
(Table 2) form part of the calcium-bound sarcomere protein
complex [188]. Two lines of evidence implicate vimentin as an
initiating autoimmune target (and peri-antigen) in RHF. First,
vimentin is modified (ADP-ribosylated) by the group A strepto-
coccal protein SpyA in a way that alters both its sequence and its
organization [189]. Second, group A streptococci are known to
bind to vimentin, particularly at sites of muscle injury [190].
Apoptotic Cleavage
Adaptive immune reponses require the joint participation and
mutual activation of CD4+ T cells and antigen-presenting cells
such as B cells. B cells become anergic under chronic low-level
exposure to antigen with limited costimulation [191]. Neverthe-
less, even anergic B cells can be activated with sufficient
stimulation [191]. Protein that is post-translationally modified
only upon apoptosis would presumably generate only low-level
exposure to B cells. A post-translationally modified protein that
forms part of a protein complex containing a somatic mutant is
liable to trigger B cell/T cell co-activation. In such a case, a CD4+
T cell specific to the mutant peri-antigen could activate a
previously anergic B cell clone. Such a mechanism could explain
why post-translationally modified proteins, particularly those
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Retrotransposition
An additional potential mechanism of coherent somatic
mutation is retrotransposition. Retrovirus [193,194] and retro-
transposon [195] integration hotspots exist, independent of
selective pressure for cell growth/survival. This form of mutation
could be relevant to Bout Onset Multiple Sclerosis (BOMS) in
which an endogenous retrovirus has been implicated [196,197], as
well as schizophrenia [198] and amyotrophic lateral sclerosis
[199]. Alternatively, retroviral expression could be a driver of
neuroinflammation [200], leading to somatic mutation at other
mutable repeat sequence.
Figure 3. Genes with high copy number internal repeats. The x-axis denotes the total length of the tandem repeat (log-scale), and the y-axis
represents the number of repeat units within the tandem repeat (log-scale). The degree of homology between repeat units is indicated by the color
of the data point. All repeats in this diagram reside in introns. Genes containing multiple disjoint repeats appear more than once.
doi:10.1371/journal.pone.0101093.g003
Figure 4. Structure of the TYR -related tandem duplications in the human reference genome. The long, high-identity duplicons make the
region susceptible to gene conversion [274].
doi:10.1371/journal.pone.0101093.g004
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Dysregulation of Protein Modification Pathways
In SSc, the presence of one antibody type is generally exclusive
of the others [201,202], suggesting several subtypes of SSc with
different mechanisms of induction. Chromosomal abnormalities
are found at high frequency in the lymphocytes of patients with
anti-centromere or anti-TOP1 antibodies, but at normal frequen-
cy in patients with anti-RNAPIII antibodies [203]. In SSc
fibroblasts, increased sumoylation of TOP1 induces deficits in
TOP1-mediated supercoiled-DNA relaxation [204] and disruption
of TOP1 is known to cause chromosomal aberrations [203].
Inhibition of sumoylation improves TOP1 function in fibroblasts
[203] and reduces fibrosis [205]. One interpretation of this data is
that anti-TOP1 SSc is a sumoylation disorder. Hyper-sumoylated
TOP1 could induce cell death via chromosomal aberrations, and
at the same time trigger an immune response. Because the post-
translationally modified protein would not be normally presented
to immature B or T cells, tolerization to modified TOP1 would not
occur. The centromere protein and SSc autoantigen CENPB is
also a sumoylation target [206–209].
A similar neoantigen-creating role for sumoylation in a subset of
patients with primary biliary cirrhosis (PBC) has previously been
proposed [210]. In patients with antibodies to PML or SP100, two
sumoylation target proteins [206–209], antibodies to SUMO2 and
SUMO1 have been observed [210]. CENPB is also an autoantigen
in PBC (Table 2). SSc and PBC are comorbid, with anti-CENPB
as a common risk factor [211,212], suggesting a shared etiology.
Schizophrenia and Autism
Schizophrenia and autism have prominent immunological
features, including HLA associations, comorbidity with autoim-
mune diseases, and associations with viral triggers and maternal
infections during pregnancy (Table 11). Immunological theories of
schizophrenia have been proposed [213].
A clue that somatic repeat mutation may contribute to
schizophrenia comes from a twin study in which a genomewide
measure of somatic trinucleotide repeat mutation was obtained
[214]. A high somatic trinucleotide mutation rate associated
selectively with the schizophrenic proband in monozygotic twins
discordant for disease [214].
Four NBPF family genes are among the top twelve in Figure 1,
including the two longest STR sequences. The four NBPF genes in
Figure 1 are located between positions 145.2 M and 148.3 M on
chromosome 1, overlapping the 1q21.1 region. NBPF genes
contain many copies of the DUF1220 element; DUF1220 copy
number is closely related to brain size, and humans have many
more copies than other primate species [215,216]. In humans,
high DUF1220 copy number correlates with macrocephaly, and
low copy number correlates with microcephaly [217,218]. Germ-
line deletions within the 1q21.1 region are associated with
schizophrenia [219,220], while duplications are associated with
autism [217]. Somatic genomic instability is likely in such highly
repetitive regions [217]. Somatic mutations early in embryonic
development [221], suggested by the link to maternal infections
during pregnancy, could lead to effects that mirror those of germ-
line mutations. Early somatic mutation also creates the possibility
that the thymus and brain express different haplotypes, preventing
thymic deletion of T cells reactive to proteins coded by a brain-
specific haplotype.
Other schizophrenia-associated genes among those in Figure 1
include IL3RA [222] and CACNG7 [223]. IL3RA encodes a
receptor for IL3 that is expressed in neurons, and IL3 expression is
correlated with brain volume [222]. CACNG7 modulates neurite
growth [224] and regulates AMPA receptor gating [225].
Several autism-related genes appear in Figure 1 and Table 4.
SNTG2 binds to neuroligins 3 and 4, genes that have been
associated with autism, and known autism-related mutations in
those neuroligins weaken the binding with SNTG2 [226]. ROBO2
is an axon-guidance protein with significantly reduced expression
in autistic brains [227]. ASMT encodes the last enzyme in the
melatonin biosynthesis pathway, low melatonin expression is
observed in autism spectrum disorders, and rare ASMT mutations
are associated with autism [228–230]. MGAM is a gene involved in
starch metabolism, with dysregulated mRNA expression in autism
[231]. Germ line loss-of-function mutations in KATNAL2 have
been associated with autism [232].
Additional autism related genes appear in Figure 3 and exhibit
structural variation in their STR sequence (File S1). Like ROBO2,
PLXNA4 is an axon-guidance protein with significantly reduced
expression in autistic brains [227]. ASMTL binds with TDO2
[233]; TDO2 is the rate-limiting enzyme in the catabolism of
tryptophan, the precursor of serotonin, which is known to be
elevated in 30% of autism cases [234].
There is a high concentration of autism-related genes among a
relatively small set of putatively mutable genes. In light of the
autoimmune features of autism (Table 11), this concentration
suggests that somatic repeat mutation may contribute to the
etiology of autism.
Table 10. Multiple mechanisms generating coherent somatic mutation, and possible examples where autoimmunity results.
Mechanism Possible Examples
Mutations at long tandem repeats T1D, HT, RA, SLE, …
Gene conversion at segmental duplications AD
Clonal expansion Paraneoplastic autoimmune diseases, GD
Oxidative stress VIM mutation in RA
RAG-dependent somatic mutation IKZF1 in RA
Pathogen Binding/Modification VIM in RHF
Retrotransposition BOMS
Apoptotic protein cleavage Many cleaved proteins are autoantigens
Dysregulation of protein modification Anti-TOP1 SSc
Environmental mutagens ENO1, VIM, FGB in RA
doi:10.1371/journal.pone.0101093.t010
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Explaining Autoimmunity
A satisfying feature of the coherent somatic mutation hypothesis
is that it provides a parsimonious yet comprehensive account of
autoimmunity. The initiation of most diseases is attributed to a
single mutable locus. A handful of diseases having several known
subtypes include more than one corresponding mutable locus.
Only four of the top sixteen genes in Figure 1 (ANKRD36C,
ANKRD36, AHNAK2, NSUN6) do not have a link with an
autoimmune disease, an autoimmune-associated mental disorder,
or atherosclerosis. These relatively uncharacterized genes are
promising candidates for future study.
The most prominent prior theory of autoimmunity is molecular
mimicry, the hypothesis that peptides similar to host proteins are
expressed by host-resident microbes, sometimes inducing an
autoimmune reaction against the host proteins. The attractive
feature of molecular mimicry has been that it provides a plausible
explanation for the known link between infection and autoimmu-
nity [235,236]. However, despite decades of research, no human
autoimmune diseases have been clearly attributed to molecular
mimicry [235,237,238].
Autoimmune diseases have historically been categorized as
organ-specific or systemic, with some diseases hard to categorize
[239]. Under the coherent somatic mutation hypothesis, both
kinds of disease have a common etiology, with the phenotype
dependent on the expression patterns of the autoantigen. A
narrow expression pattern (such as PTPRN2) leads to an organ-
specific disease (T1D), while a widely expressed protein complex
(TTC34/PPP4C as proposed in this report) leads to a systemic
disease (SLE).
The incidence of each of several autoimmune diseases has been
rising in recent years [240], as has the apparent incidence of
autism [241]. The ‘‘hygiene hypothesis’’ states that autoimmune
disease is linked to the absence of infections, through one of several
possible immunoregulatory mechanisms [240]. Some infections
that are protective if they occur early in development are possible
triggers of autoimmunity if they occur later [240]. The present
theory is consistent with a variant of the hygiene hypothesis in
which tolerance to coherently mutated antigens is dependent on
the early generation of such mutants. Infections or other
inflammatory stimuli would increase the rate of somatic mutation,
allowing for more efficient induction of peripheral tolerance. In
the absence of peripheral tolerance, late generation of somatic
mutants could induce autoimmunity. Alternative hypotheses based
on increasing exposure to environmental mutagens [242,243] are
also consistent with an etiology dependent on somatic mutation.
Autoinflammatory Disease
Several non-autoimmune diseases may also be caused by
somatic mutation of highly mutable repeat sequence in the
context of inflammation. Atopic dermatitis and icthyosis vulgaris
are inflammatory skin conditions caused by inactivating germ-line
mutations of the FLG gene in some cases [244,245]. Somatic
inactivating mutations of the 10.8 kb coding tandem repeat in
FLG, reinforced by local inflammation, could contribute to the
pathogenesis of these conditions. An accumulation of somatic
mutations in PTPRN2 (without autoimmunity) could lead to
glucose intolerance [246]. Similar mechanisms could underlie
various autoinflammatory conditions [247].
Genetics
Our study is limited by its reliance on a single human genome
for long repetitive sequence. Some reference alleles are much
shorter than those typically observed in the population (e.g.,
MUC1 [248,249]). It is likely that long repetitive sequence is highly
variable in the population [37,38,250], and that variations in
germ-line sequence would modulate disease risk as seen for CR1,
LPA, HP and DMBT1. Nevertheless, primary autoantigens whose
genes contain long repeats were identified in a presumably healthy
random individual, suggesting that, at least for those genes, all
humans have some degree of somatic mutation and risk for
disease.
Linkage based analysis of sequence variation in a population
would not identify mutable repetitive regions because the high
germ-line mutation rate would rapidly eliminate any linkage
disequilibrium with adjacent sequence [157]. In contrast, there are
likely to be few germ-line mutations within a pedigree, meaning
that estimates of heritability [251] will include any effects of
commonly inherited mutable sequence. Together, these effects
could explain at least some of the missing heritability observed in
many genomewide association studies [252–254].
Immunological Aspects
Not all somatic mutation is likely to be immunogenic, even in
protein-coding sequence. Somatic mosaicism observed in triplet
repeat expansion diseases [255] would not generate immunogenic
protein if the repeat length is longer than the fragment expressible
in MHC molecules (8–10 amino acids for MHC-I, 15–24 amino
acids for MHC-II). On the other hand, a long triplet repeat could
be vulnerable to somatic deletions, yielding a short, potentially
immunogenic peptide repeat.
Keratinocytes express FLG [256] and are non-professional
antigen presenting cells (APCs) [257]. Pancreatic beta cells express
PTPRN2, and thyroid epithelial cells express TPO; both of these
cell types are also non-professional APCs. The purpose of antigen
presentation by such cells is assumed to be tolerization in the
absence of costimulatory molecules [258], which seems appropri-
ate in the case of three primary (and putatively mutable)
autoantigens. The presence of antigen presentation on these cell
types may have allowed the evolution of mutable genes without
significant risk of abrogating tolerance. Alternatively, antigen
presentation within these cell types may have evolved as a response
to selective pressure for longer repeat sequences in these genes.
While T cell tolerance can be induced by the administration of
peptides [259,260], attempts to induce tolerance in humans
suffering from autoimmune disease have been largely unsuccessful
[261]. Nevertheless, the success of these attempts is critically
dependent on the peptide sequence used. The coherent somatic
mutation hypothesis suggests that for intronic repeats, the initial
immunogenic proteins may be mis-spliced or truncated forms of a
native protein. Peptides covering the splice or truncation
boundaries of putative mutant protein would be natural candi-
dates for tolerance induction.
Validation
Many of the high prevalence diseases in Table 1 have been
specifically associated with mutable antigens or peri-antigens in the
present report. Some more speculative hypotheses for the
involvement of somatic mutation in other diseases are presented
in File S1. The proposed associations should be considered
tentative, and subject to experimental validation. For reasons
described previously and below, experimental validation may be
technically difficult.
Recent sequencing advances have the potential to accurately
sequence long repetitive regions [250]. Accurately sequencing
many cells in search of rare somatic mutants will require
significantly more effort, although new technologies will help [6].
Obtaining putatively mutated cells from sites of autoimmune
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damage is challenging, since such cells would be subject to
immunological destruction as soon as the mutation occurs.
Conclusions
The coherent somatic mutation hypothesis states that recurrent
or clonal somatic mutation underlies the initiation of autoimmune
disease. Long STR sequence is likely to be somatically mutable in
vivo, motivating the present study. A highly significant association
between three primary autoantigens (covering four autoimmune
diseases) and long STR sequence was established. Additional
autoantigens and peri-antigens were identified among genes
spanning long STR sequence, and among genes with other
known markers of somatic mutation. The work presented here
could lead to a partial resolution of the mystery of why particular
proteins are targets of autoimmune destruction [50]. Experimental
validation of the specific predictions made here is the next step.
Materials and Methods
Genome coordinates use the GRCh37 (hg19) sequence. Gene
names use HGNC approved nomenclature. Queries were
submitted to the UCSC MySQL database server [64] and
processed as described below. The SQL queries can be found in
File S1. Gene transcripts were required to be protein-coding
according to GENCODE version 17 [262] or (for Queries 2 and 6)
RefSeq [263].
Identifying Genes with Intragenic Repeats
Query 1 was submitted to obtain genes containing long or
frequent repeats. The output from this query was edited as follows:
N Genes not on the reference chromosomes were removed. Only
one such gene (MGC39584/AC018692.2 on chr4_gl000193_
random) had length over 5 kb and none had a repeat count
over 100.
N For genes occurring on both the X and Y chromosomes, only
the X chromosome instance was retained.
N TMRF often generated multiple repeat candidates for a region
with the periods of the candidates being multiples of the
shortest period. In such cases, only the shortest-period
candidate with the highest repeat-unit count was kept, even
if it spanned a slightly smaller region.
N When TMRF generated a consensus repeat unit that was itself
repetitive (e.g., AGTTAGTTAGTT) the TMRF entry was
replaced by one with a shorter repeat unit (e.g., AGTT) and a
higher repeat-unit count, retaining the degree of identity from
the longer sequence. Examples include VPS53 (in which a
96 bp repeat is itself made of 3 instances of a 32 bp repeat),
MUC4 (in which a 96 bp repeat consists of two consecutive
instances of a 48 bp repeat), and MAL (with an 8 bp
AGTGAGTG repeat).
N In a small number of cases, TMRF generated multiple
essentially contiguous repeats with the same period and
consensus sequence. The only such case where the repeat
was either more than 5 kb long or contained more than 600
repeat units was PTPRN2 (chr7:158122660–158135328) where
the contiguous repeat records were combined into a single
longer 12.6 kb repeat.
To see whether the output was dependent on the source of the
gene annotations, I reformulated the query as Query 2 using
RefSeq [263]. The following differences were noted for repeats
longer than 5 kb:
N There was some discrepant labeling of the NBPF genes. The
NBPF repeat sequences were the same, with the exception of
one NBPF10 repeat (see below).
N The following genes/repeat-lengths were identified by GEN-
CODE but not RefSeq: ANKRD36C/49539; FAM230A,
USP1/7516; PLEKHB2/6521; ANKRD36C/6410; FAM182B/
6292.
N The following genes/repeat-lengths were identified by RefSeq
but not GENCODE: NBPF10/15997; ANKRD36B/25486;
MUC19/8607.
N A large majority of repeats were common to the two
annotations, with the differences mentioned above largely
due to differences in the labeling of a gene transcript as protein
coding.
The differences between the two annotations appear to be
small. The MUC19 transcript identified by RefSeq may have
immunological significance given the association of MUC19 with
Crohn’s disease and ulcerative colitis [105,264,265].
Genes that span gaps in the human assembly where the gaps are
presumed to include repetitive sequence (e.g., MUC5AC [250]) are
absent from the query result. Applying the tandem repeat finder
algorithm [63] to the MUC5AC exon 31 sequence reported by Guo
et al [250] revealed a longest tandem repeat of 1.6 kb.
Table 11. Immunological features of autism and schizophrenia.
Feature Autism Schizophrenia
HLA Association Yes [441,442] Yes [442,443]
Co-morbidity with autoimmune disease Yes [441,444–446] Yes [447–449]
Viral triggers for disease Yes [450] Yes [450,451]
Association with maternal infection
during pregnancy.
Yes [441] Yes [452]
Autoantibodies Brain-specific antibodies in mothers and probands
[441,446,453,454]; Anti-nuclear antibodies [446,455]
Yes [456]
Other Gene expression changes reminiscent of
autoimmunity [457]; NK cell dysregulation [458];
Amelioration of aberrant behaviors during fever [459]
Various immunological abnormalities [460–462];
differentially expressed genes involve immune pathways
[463]
doi:10.1371/journal.pone.0101093.t011
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Identifying Genes Spanning Long Segmental
Duplications
Query 3 was used to identify a preliminary set of segmental
duplications occuring within protein-coding genes, using the
segmental duplication track [266] of the UCSC MySQL database
server [64]. At least one duplicon was required to occur entirely
within the gene sequence. The structure of the identified
segmental duplications was examined using the UCSC genome
browser. Where more than two contiguous tandem duplications
exist (CR1, NEB, SPDYE3), the records for the gene were
combined into a single record for the longer compound tandem
repeat. When multiple segmental duplications overlapped (TTC34)
only the longer duplication was retained.
Additional Queries
Query 4 was used to identify long self-alignments (score at least
60) within protein-coding genes, using the self-alignment track
[267] of the UCSC MySQL database server [64]. Query 5 was
used to identify repeats constituting almost an entire intron within
a gene. Query 6 was used to identify long repeats in the mouse
genome; repeats are required to overlap a protein-coding RefSeq
gene, including 5 kb of sequence upstream of the gene start site.
Query 7 was used to identify pairs of long repeats where the
second repeat unit is the reverse complement of the first. The
purpose of this analysis is to understand the genomewide
significance of this feature of the NSUN6 repeats (File S1). The
output of this query was filtered to remove sequences on unplaced
chromosomes and rows in which the two repeat sequences are not
reverse complements. Queries 8 through 12 identify structural
variation at STR loci utilizing information from the DGV
database [268–270] (File S1).
Significance of Autoantigen Over-Representation in Gene
Lists
Primary Autoantigens. To determine the statistical signifi-
cance of a set of primary autoantigens within a gene list, an
estimate of the number of known primary autoantigens for
common autoimmune diseases is required. Based on Table 1,
there are nineteen known primary autoantigens for those diseases.
This number includes pANCA, a category covering five proteins
in UC [271], and ribosomal P (3 proteins), so a more precise
estimate of the number of genes is 25. The null hypothesis H0
states that each gene associated with a primary autoantigen is
equally likely to appear anywhere in the ranked list of genes. There
are 20,330 protein-coding genes in GENCODE V17 [272].
Choosing the top eleven genes is therefore well approximated by a
binomial process, where a selected gene has a 25=20330&0:0012
probability of being a primary autoantigen under the null
hypothesis.
I apply an exact one-sided binomial test of goodness of fit. The
p-value for 3 or more of the top 11 genes being primary
autoantigens under the null hypothesis is 3:0|10{7: The
significance is robust to the size of the prefix of the gene list. For
example, taking the top 35 genes rather than the top 11 yields
pv1:2|10{5: One can therefore reject the null hypothesis and
conclude that the overrepresentation of primary autoantigens near
the top of the list is highly significant.
Autoantigens. Determining the significance of a set of
autoantigens within a gene list requires an estimate of the total
number of autoantigens. Stadler et al. [54] tabulate 348 known
autoantigens, but this list is incomplete (e.g., it does not include
FLG or PKP3). For the purposes of determining a p value, 400
autoantigens and 20,330 protein-coding genes [272] are assumed
for a one-sided binomial goodness of fit test. All p values calculated
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